Home HIIT bike workout targets fatty liver in new trial

NCT ID NCT07177963

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether an 8-week home-based high-intensity interval training (HIIT) program, done on a stationary bike and supervised remotely, can reduce liver fat and improve other health measures in 54 adults aged 35-65 with metabolic dysfunction-associated fatty liver disease (MAFLD). Participants will do short bursts of intense pedaling followed by easy recovery, with the workout tailored to their fitness level. The goal is to see if this time-efficient exercise is safe, feasible, and effective for managing MAFLD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
high-intensity interval training (HIIT) on a stationary bike
What this could lead to
If it works, this could offer a time-efficient, home-based exercise option to reduce liver fat and improve metabolic health in people with MAFLD.
What could go wrong
This is a small, early-stage trial with only 54 participants and no control group for comparison. Results may not apply to everyone, and the exercise program may be too intense for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Beijing Youan Hospital, Capital Medical University

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • The Fifth Medical Center, Chinese PLA General Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.